Cited by 15,011Multiple Sclerosis Research StudiesHealth Systems, Economic Evaluations, Quality of LifeVoice and Speech Disorders

The DOI matches its Crossref record; 12 of the 13 references it cites were found in a registry or an index.

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Kurtzke, John F.·1983·Neurology

DOI 10.1212/wnl.33.11.1444

Open this paper in CoChat — free account

Abstract

One method of evaluating the degree of neurologic impairment in MS has been the combination of grades (0 = normal to 5 or 6 = maximal impairment) within 8 Functional Systems (FS) and an overall Disability Status Scale (DSS) that had steps from 0 (normal) to 10 (death due to MS). A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 . . . 9) now divided into two (1.0, 1.5, 2.0 . . . 9.5). The lower portion is obligatorily defined by Functional System grades. The FS are Pyramidal, Cerebellar, Brain Stem, Sensory, Bowel & Bladder, Visual, Cerebral, and Other; the Sensory and Bowel & Bladder Systems have been revised. Patterns of FS and relations of FS by type and grade to the DSS are demonstrated.

Integrity signals

Registry

Crossref · 10.1212/wnl.33.11.1444

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

On the evaluation of disability in multiple sclerosis
Kurtzke, J. F. (1961) · Neurology · doi:10.1212/wnl.11.8.686 · Cited by 330
Further notes on disability evaluation in multiple sclerosis, with scale modifications
Kurtzke, J. F. (1965) · Neurology · doi:10.1212/wnl.15.7.654 · Cited by 309
A New Scale for Evaluating Disability in Multiple Sclerosis
Kurtzke, J. F. (1955) · Neurology · doi:10.1212/wnl.5.8.580 · Cited by 305
Appreciating the consequences of disease: the international classification of impairments, disabilities, and handicaps.
Wood, P. (1980) · PubMed · Cited by 247
NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AND THE DISABILITY STATUS SCALE
Kurtzke, J. F. (1970) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1970.tb05808.x · Cited by 156
A PROPOSAL FOR A UNIFORM MINIMAL RECORD OF DISABILITY IN MULTIPLE SCLEROSIS
Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05548.x · Cited by 127
STUDIES ON THE NATURAL HISTORY OF MULTIPLE SCLEROSIS 6. Clinical and Laboratory Findings at First Diagnosis
Kurtzke, J. F., Beebe, G. W., Nagler, B., Auth, T. L., Kurland, L. T., & Nefzger, M. D. (1972) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1972.tb07525.x · Cited by 68
THE SOCIO-ECONOMIC SCALE
Mellerup, E., Fog, T., Raun, N. E., Colville, P., de Rham, B., Hannah, B., & Kurtzke, J. F. (1981) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1981.tb05549.x · Cited by 53
The effects of isoniazid on patients with multiple sclerosis; preliminary report.
Kurtzke, J. F., & Berlin, L. (1954) · PubMed · doi:10.1164/art.1954.70.4.577 · Cited by 23
ACUTE RESPIRATORY FAILURE IN MULTIPLE SCLEROSIS AND ITS MANAGEMENT
Guthrie, T. C., Kurtzke, J. F., & BERLIN, L. (1952) · Annals of Internal Medicine · doi:10.7326/0003-4819-37-6-1197 · Cited by 20

Show all 13 references

Sorted by citations

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdová, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., LUBLIN, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,433
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E. W., O'Connor, P. W., Polman, C. H., Hohlfeld, R., Calabresi, P. A., Selmaj, K. W., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,670
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. Μ., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,446
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comı, G., Hartung, H., Khatri, B. O., Montalbán, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,220
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,144
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
Hauser, S. L., Bar-Or, A., Comi, G., Giovannoni, G., Hartung, H.-P., Hemmer, B., Lublin, F., Montalban, X., Rammohan, K. W., Selmaj, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1601277 · Cited by 2,021
Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis
Paty, D. W., Li, D. K. B., the UBC MS/MRI Study Group, & the IFNB Multiple Sclerosis Study Group (1993) · Neurology · doi:10.1212/wnl.43.4.662 · Cited by 1,964
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life
Patrick, D. L., & Deyo, R. A. (1989) · Medical Care · doi:10.1097/00005650-198903001-00018 · Cited by 1,779
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Gold, R., Kappos, L., Arnold, D. L., Bar‐Or, A., Giovannoni, G., Selmaj, K. W., Tornatore, C., Sweetser, M. T., Yang, M., Sheikh, S. I., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114287 · Cited by 1,765
Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,485
Multiple sclerosis
Filippi, M., Bar-Or, A., Piehl, F., Preziosa, P., Solari, A., Vukusic, S., & Rocca, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0041-4 · Cited by 1,562
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Fox, R. J., Miller, D. H., Phillips, J. T., Hutchinson, M., Havrdová, E., Kita, M., Yang, M., Raghupathi, K., Novas, M., Sweetser, M. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206328 · Cited by 1,371
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E. W., LUBLIN, F. D., Weinstock‐Guttman, B., Wynn, D. R., Lynn, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044396 · Cited by 1,342
Rate of Pregnancy-Related Relapse in Multiple Sclerosis
Confavreux, C., Hutchinson, M., Hours, M. M., Cortinovis-Tourniaire, P., & Moreau, T. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390501 · Cited by 1,559
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,328
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
A controlled trial of natalizumab for relapsing multiple sclerosis.
Miller, D. H., Khan, O., Sheremata, W., Blumhardt, L., Rice, G., Libonati, M., Willmer-Hulme, A., Dalton, C., Miszkiel, K., & O'Connor, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,265
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Development of a multiple sclerosis functional composite as a clinical trial outcome measure
Cutter, G. (1999) · Brain · doi:10.1093/brain/122.5.871 · Cited by 1,191
Diagnosis and Treatment of Multiple Sclerosis: A Review
McGinley, M. P., Goldschmidt, C. H., & Rae-Grant, A. D. (2021) · JAMA · doi:10.1001/jama.2020.26858 · Cited by 1,205
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164
Cost of disorders of the brain in Europe
Andlin‐Sobocki, P., Jönsson, B., Wïttchen, H., & Olesen, J. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01202.x · Cited by 1,154
Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Wallin, M. T., Culpepper, W. J., Nichols, E., Bhutta, Z. A., Gebrehiwot, T. T., Hay, S. I., Khalil, I. A., Krohn, K. J., Liang, X., Naghavi, M., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30443-5 · Cited by 1,134
A health-related quality of life measure for multiple sclerosis
Vickrey, B. G., Hays, R. D., Harooni, R., Myers, L. W., & Ellison, G. W. (1995) · Quality of Life Research · doi:10.1007/bf02260859 · Cited by 1,132
The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure
Hobart, J. (2001) · Brain · doi:10.1093/brain/124.5.962 · Cited by 1,144
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Kappos, L., Antel, J. P., Comi, G., Montalbán, X., O'Connor, P. W., Polman, C. H., Haas, T., Korn, A., Karlsson, G., & Radue, E. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052643 · Cited by 1,058
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, Ó., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,042
A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor.
Schuurman, P., Bosch, D. A., Bossuyt, P., Bonsel, G., van Someren, E. V., de Bie, R. D., Merkus, M., & Speelman, J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002173420703 · Cited by 1,065
The impact of fatigue on patients with multiple sclerosis
Fisk, J. D., Pontefract, A., Ritvo, P. G., Archibald, C. J., & Murray, T. J. (1994) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100048691 · Cited by 1,025
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Giovannoni, G., Comı, G., Cook, S. D., Rammohan, K. W., Rieckmann, P., Sørensen, P. S., Vermersch, P., Chang, P., Hamlett, A., Musch, B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0902533 · Cited by 1,021
TNF neutralization in MS
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) · Neurology · doi:10.1212/wnl.53.3.457 · Cited by 1,068
Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
The CAMMS Trial Investigators (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,021
Multiple Sclerosis: Current Knowledge and Future Outlook
Kamm, C. P., Uitdehaag, B. M. J., & Polman, C. H. (2014) · European Neurology · doi:10.1159/000360528 · Cited by 1,011
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process
Confavreux, C. (2003) · Brain · doi:10.1093/brain/awg081 · Cited by 1,017
The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment
Fischer, J. S., Rudick, R. A., Cutter, G., & Reingold, S. C. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500409 · Cited by 997
Fatigue in Multiple Sclerosis
Krupp, L., Alvarez, L., LaRocca, N. G., & Lc, S. (1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520280085020 · Cited by 999
Premyelinating Oligodendrocytes in Chronic Lesions of Multiple Sclerosis
Chang, A., Tourtellotte, W. W., Rudick, R., & Trapp, B. D. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa010994 · Cited by 991
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Kappos, L., Bar-Or, A., Cree, B. A. C., Fox, R. J., Giovannoni, G., Gold, R., Vermersch, P., Arnold, D. L., Arnould, S., Scherz, T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30475-6 · Cited by 942
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial
Hartung, H., Gonsette, R. E., König, N., Kwieciński, H., Guseo, A., Morrissey, S., Krapf, H., & Zwingers, T. (2002) · The Lancet · doi:10.1016/s0140-6736(02)12023-x · Cited by 944
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial
Hawker, K., O'Connor, P. W., Freedman, M. S., Calabresi, P. A., Antel, J. P., Simon, J. H., Hauser, S. L., Waubant, E. L., Vollmer, T. L., PANITCH, H. S., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 951
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F. C., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0718-0 · Cited by 900
Reliability and validity of arm function assessment with standardized guidelines for the Fugl-Meyer Test, Action Research Arm Test and Box and Block Test: a multicentre study
Platz, T., Pinkowski, C., van Wijck, F., Kim, I.-H., Bella, P. D., & Johnson, G. R. (2005) · Clinical Rehabilitation · doi:10.1191/0269215505cr832oa · Cited by 892
Untitled work
(1999) · doi:10.1002/1531-8249(199912)46:6
Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Pittock, S. J., Berthele, A., Fujihara, K., Kim, H. J., Levy, M., Palace, J. A., Nakashima, I., Terzi, M., Totolyan, N. A., Viswanathan, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900866 · Cited by 887
Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity
Roxburgh, R. H. S. R., Seaman, S. R., Masterman, T., Hensiek, A. E., Sawcer, S. J., Vukusic, S., Achiti, I., Confavreux, C., Coustans, M., le Page, E., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000156155.19270.f8 · Cited by 963
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861
A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
Teunissen, C. E., Petzold, A., Bennett, J. L., Berven, F. S., Brundin, L., Comabella, M., Franciotta, D., Frederiksen, J. L., Fleming, J. O., Furlan, R., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c47cc2 · Cited by 845
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial
Calabresi, P. A., Radue, E. W., Goodin, D. S., Jeffery, D., Rammohan, K. W., Reder, A. T., Vollmer, T. L., Agius, M. A., Kappos, L., Stites, T. E., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70049-3 · Cited by 845
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand
Bielekova, B., Goodwin, B. L., Richert, N. D., Cortese, I. C. M., Kondo, T., Afshar, G., Gran, B., Eaton, J. K., Antel, J. P., Frank, J. A., et al. (2000) · Nature Medicine · doi:10.1038/80516 · Cited by 823
Measuring the impact of MS on walking ability
Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R. M., & Thompson, A. J. (2003) · Neurology · doi:10.1212/wnl.60.1.31 · Cited by 826
Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis
Sharief, M. K., & Hentges, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108153250704 · Cited by 810
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)
Benedict, R. H. B., Cookfair, D. L., Gavett, R. A., Gunther, M. W., Munschauer, F. E., Garg, N., & Weinstock‐Guttman, B. (2006) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617706060723 · Cited by 800
Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain
Schmierer, K., Scaravilli, F., Altmann, D. R., Barker, G. J., & Miller, D. H. (2004) · Annals of Neurology · doi:10.1002/ana.20202 · Cited by 777
Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis
Learmonth, Y. C., Motl, R. W., Sandroff, B. M., Pula, J. H., & Cadavid, D. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-37 · Cited by 790
Impact of aerobic training on fitness and quality of life in multiple sclerosis
Petajan, J. H., Gappmaier, E., White, A. T., SPENCER, M. K., Mino, L., & Hicks, R. W. (1996) · Annals of Neurology · doi:10.1002/ana.410390405 · Cited by 756
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis
Fisniku, L. K., Brex, P. A., Altmann, D. R., Miszkiel, K. A., Benton, C. E., Lanyon, R., Thompson, A. J., & Miller, D. H. (2008) · Brain · doi:10.1093/brain/awm329 · Cited by 897
Treatment of multiple sclerosis with gamma interferon
PANITCH, H. S., Hirsch, R. L., Schindler, J. D., & Johnson, K. P. (1987) · Neurology · doi:10.1212/wnl.37.7.1097 · Cited by 752
Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis
Matusevičius, D., Kivisäkk, P., He, B., Kostulas, N., Özenci, V., Fredrikson, S., & Link, H. (1999) · Multiple Sclerosis Journal · doi:10.1177/135245859900500206 · Cited by 751
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Kappos, L., Li, D., Calabresi, P. A., O'Connor, P. W., Bar‐Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61649-8 · Cited by 743
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
Rudick, R. A., Fisher, E., Lee, J.-C., Simon, J. H., & Jacobs, L. (1999) · Neurology · doi:10.1212/wnl.53.8.1698 · Cited by 736
Ofatumumab versus Teriflunomide in Multiple Sclerosis
Hauser, S. L., Bar‐Or, A., Cohen, J. A., Comı, G., Correale, J. D., Coyle, P. K., Cross, A. H., Seze, J. D., Leppert, D., Montalbán, X., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917246 · Cited by 765
Acute disseminated encephalomyelitis
Tenembaum, S. N., Chamoles, N., & Fejerman, N. (2002) · Neurology · doi:10.1212/wnl.59.8.1224 · Cited by 708
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi, G., Filippi, M., & Wolinsky, J. S. (2001) · PubMed · Cited by 688
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Rog, D. J., Nurmikko, T. J., Friede, T., & Young, C. A. (2005) · Neurology · doi:10.1212/01.wnl.0000176753.45410.8b · Cited by 679
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H., Miller, D., Montalbán, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 677
Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls
Goldman, M. D., Marrie, R. A., & Cohen, J. A. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458507082607 · Cited by 675
Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis
Zamboni, P., Galeotti, R., Menegatti, E., Malagoni, A. M., Tacconi, G., Dall'Ara, S., Bartolomei, I., & Salvi, F. (2008) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.157164 · Cited by 671
The epidemiology of multiple sclerosis in Europe
Pugliatti, M., Rosati, G., Carton, H., Riise, T., Drulovic, J., Vécsei, L., & Milanov, I. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01342.x · Cited by 654
Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia
Glass, J. D., Fedor, H. L., Wesselingh, S. L., & McArthur, J. C. (1995) · Annals of Neurology · doi:10.1002/ana.410380510 · Cited by 661
Relation of Visual Function to Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Fisher, J. P., Jacobs, D. A., Markowitz, C., Galetta, S. L., Volpe, N. J., Nano-Schiavi, M. L., Baier, M. L., Frohman, E. M., WINSLOW, H., & Frohman, T. C. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.10.040 · Cited by 658
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
Comi, G., Filippi, M., Wolinsky, J. S., & European/Canadian Glatiramer Acetate Study Group (2001) · Annals of Neurology · doi:10.1002/ana.64 · Cited by 768
Beyond unfavorable thinking: the illness cognition questionnaire for chronic diseases
Evers, A. W. M., Kraaimaat, F. W., van Lankveld, W., Jongen, P. J. H., Jacobs, J. W. G., & Bijlsma, J. W. J. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.69.6.1026 · Cited by 657
An open label study of the effects of rituximab in neuromyelitis optica
Cree, B., Lamb, S., Morgan, K., Chen, A., Waubant, E. L., & Genain, C. P. (2005) · Neurology · doi:10.1212/01.wnl.0000159399.81861.d5 · Cited by 646
Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis
Meyer-Moock, S., Feng, Y., Maeurer, M., Dippel, F. W., & Kohlmann, T. (2014) · BMC Neurology · doi:10.1186/1471-2377-14-58 · Cited by 646
Spinal cord atrophy and disability in multiple sclerosis
Losseff, N. A., Webb, S. L., O’Riordan, J. I., Page, R., Wang, L., Barker, G. J., Tofts, P. S., McDonald, W. I., Miller, D., & Thompson, A. J. (1996) · Brain · doi:10.1093/brain/119.3.701 · Cited by 642
Cognitive Dysfunction in Early-Onset Multiple Sclerosis
Amato, M. P., Ponziani, G., Siracusa, G., & Sorbi, S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.10.1602 · Cited by 642
Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters
Flachenecker, P., Kümpfel, T., Kallmann, B. A., Gottschalk, M., Grauer, O. M., Rieckmann, P., Trenkwalder, C., & Toyka, K. V. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms839oa · Cited by 635
Randomized, comparative study of interferon β-1a treatment regimens in MS
PANITCH, H. S., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O'Connor, P. W., Ed, M., Li, D., & Weinshenker, B. G. (2002) · Neurology · doi:10.1212/01.wnl.0000034080.43681.da · Cited by 631
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis
Werring, D. J., Clark, C. A., Barker, G. J., Thompson, A. J., & Miller, D. H. (1999) · Neurology · doi:10.1212/wnl.52.8.1626 · Cited by 621
Natural History of Multiple Sclerosis with Childhood Onset
Renoux, C., Vukusic, S., Mikaeloff, Y., Edan, G., Clanet, M., Dubois, B., Debouverie, M., Brochet, B., Lebrun‐Frénay, C., Pelletier, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067597 · Cited by 598
Plasma exchange for severe attacks of CNS demyelination: Predictors of response
Keegan, M., Pineda, A. A., McClelland, R. L., Darby, C. H., Rodriguez, M., & Weinshenker, B. G. (2002) · Neurology · doi:10.1212/wnl.58.1.143 · Cited by 597
Evidence for a two-stage disability progression in multiple sclerosis
Leray, E., Yaouanq, J., Page, E. L., Coustans, M., Laplaud, D. A., Oger, J. J.-F., & Edan, G. (2010) · Brain · doi:10.1093/brain/awq076 · Cited by 621
Randomized controlled trial of yoga and exercise in multiple sclerosis
Oken, B., Kishiyama, S., Zajdel, D., Bourdette, D., Carlsen, J., Haas, M., Hugos, C. L., Kraemer, D., Lawrence, J., & Mass, M. (2004) · Neurology · doi:10.1212/01.wnl.0000129534.88602.5c · Cited by 610
BREAKDOWN OF THE BLOOD-BRAIN BARRIER PRECEDES SYMPTOMS AND OTHER MRI SIGNS OF NEW LESIONS IN MULTIPLE SCLEROSIS: PATHOGENETIC AND CLINICAL IMPLICATIONS
KERMODE, A. G., THOMPSON, A. J., TOFTS, P., MACMANUS, D. G., KENDALL, B. E., KINGSLEY, D. P. E., MOSELEY, I. F., RUDGE, P., & MCDONALD, W. I. (1990) · Brain · doi:10.1093/brain/113.5.1477 · Cited by 578
Intermittent Fasting Confers Protection in CNS Autoimmunity by Altering the Gut Microbiota
Cignarella, F., Cantoni, C., Ghezzi, L., Salter, A., Dorsett, Y., Chen, L., Phillips, D., Weinstock, G. M., Fontana, L., Cross, A. H., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.05.006 · Cited by 568
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
Confavreux, C., O'Connor, P. W., Comı, G., Freedman, M. S., Miller, A., Olsson, T. P., Wolinsky, J. S., Bagulho, T., Delhay, J.-L., Dukovic, D., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70308-9 · Cited by 579
Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination
Ramanathan, S., Mohammad, S. S., Tantsis, E. M., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner‐Scott, J., Vucic, S., et al. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 574
The peripheral benzodiazepine binding site in the brain in multiple sclerosis
Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G., Wegner, F., Giovannoni, G., Miller, D. H., et al. (2000) · Brain · doi:10.1093/brain/123.11.2321 · Cited by 661
PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS
The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group (2001) · Neurology · doi:10.1212/wnl.56.12.1628 · Cited by 570
Common brain disorders are associated with heritable patterns of apparent aging of the brain
Kaufmann, T., van der Meer, D., Doan, N. T., Schwarz, E., Lund, M. J., Agartz, I., Alnæs, D., Barch, D. M., Baur‐Streubel, R., Bertolino, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0471-7 · Cited by 575
Depressive Symptoms and Severity of Illness in Multiple Sclerosis: Epidemiologic Study of a Large Community Sample
Chwastiak, L., Ehde, D. M., Gibbons, L. E., Sullivan, M., Bowen, J. D., & Kraft, G. H. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1862 · Cited by 555
The role of magnetic resonance techniques in understanding and managing multiple sclerosis
Miller, D. (1998) · Brain · doi:10.1093/brain/121.1.3 · Cited by 553
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
Goodman, A. D., Brown, T. R., Krupp, L., Schapiro, R. T., Schwid, S. R., Cohen, R., Marinucci, L. N., & Blight, A. R. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60442-6 · Cited by 552

Authors: Kurtzke, J. F.
Affiliations: Georgetown University (US)
Corresponding author: Kurtzke, John F.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1983-11
Volume: 33
Issue: 11
Pages: 1444-1444
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.33.11.1444
OpenAlex: W2112165124
Cited by: 15,011
References: 13
Citations by year: 2026: 474 · 2025: 622 · 2024: 692 · 2023: 648 · 2022: 722 · 2021: 781 · 2020: 764 · 2019: 648 · 2018: 603 · 2017: 592 · 2016: 657 · 2015: 634 · 2014: 632 · 2013: 586 · 2012: 581
FWCI: 9.57
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Health Sciences › Health Professions › Speech and Hearing › Voice and Speech Disorders
Keywords: multiple sclerosis, Expanded Disability Status Scale, disability assessment, neurological deficit, functional systems, pyramidal system, cerebellar function, brainstem, sensory impairment, bowel and bladder dysfunction, visual impairment
MeSH terms: Humans, Multiple Sclerosis, Nervous System Diseases, Neurologic Examination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks